2:11PM ET 6/24/2022 MT NewswiresExelixis (EXEL) shares were up more than 3% in Friday afternoon trading after BMO Capital initiated the stock coverage at outperform and set the price...
4:54AM ET 6/24/2022 MT NewswiresExelixis (EXEL) has an average rating of outperform and price targets ranging from $18 to $35, according to analysts polled by Capital IQ. (MT Newswires...
10:49AM ET 6/21/2022 MT NewswiresExelixis (EXEL) said Tuesday it has initiated a phase 3 trial evaluating its XL092 treatment in combination with either atezolizumab or regorafenib in...
6:25AM ET 6/16/2022 MT NewswiresExelixis (EXEL) said Wednesday that it entered an option and license agreement with Sweden's BioInvent International AB to discover new antibodies for...